healthcare
- Home
- healthcare
Public
Research Note - Rise of the Cashless Economy
- Review
- June 3, 2020
Is this the most hated company on the ASX?
- Review
- August 16, 2019
Latest Articles
SUDA gains regulatory approval for sale of insomnia treatment spray
Australians suffering from insomnia could soon have relief from the disorder with SUDA Pharmaceuticals (ASX: SUD) gaining approval from the Therapeutics Goods Administration (TGA) for the sale of their ZolpiMist spray as a treatment for short-term insomnia. The regulatory approval enables ZolpiMist to be sold in Australia and will assist their strategic partners in other
Read MorePublic
IPO Watch August: 4D Medical
While the number of companies set to list on the ASX is still quieter than usual, we are continuing to see many healthcare companies viewing COVID-19 as an opportunity to make their public debut. 4D Medical are a Melbourne-based medical technology company, who have spent the last 15 years developing lung imaging software. The ‘software
Read MorePublic
InteliCare secures first NSW orders for contact-free aged care systems
Amid the raging situation in Victoria with rising COVID-19 cases in aged care facilities, tech company InteliCare (ASX: ICR) has secured a cornerstone order for their aged and disability care system which enables families to monitor loved ones contact-free, without invading their privacy. The order for 120 InteliLiving Systems was placed by independent care provider
Read MorePublic
Alcidion secures major UK hospital network for Patientrack health monitoring
Smart healthcare continues to make strides in the United Kingdom with healthtech company Alcidion (ASX: ALC) to deploy their Patientrack monitoring system across the NHS Lanarkshire, the third largest health board in Scotland. With approximately 12,000 staff working across communities, health centres, clinics and three district hospitals, the 5-year agreement will see Alcidion roll out
Read MorePublic
IPO Watch July: Aroa Biosurgery
Soft tissue regeneration company, Aroa Biosurgery, is set to list on the ASX at the end of the month. The company is looking to raise $45m at an offer price of $0.75, ultimately giving the Auckland-based company a proposed market capitalisation of $225m. Aroa’s technology is centred around soft tissue regeneration and the complex wound
Read MorePublic
Healthia primed for post-COVID acquisition growth with keys to ‘war chest’
Having emerged from the coronavirus pandemic in good shape, Healthia (ASX: HLA) is poised to deploy its $27 million ‘war chest’ for further acquisitions in the fragmented podiatry and physiotherapy sectors. In May the company settled the $5 million purchase of The Foot and Ankle Clinic, which consists of 12 clinics in Melbourne and regional
Read MorePublic